Seaside secures $30 million to fund autism and Fragile X syndrome candidates
18 September 2009
Christopher Spillane
Please Login to read the full article.
18 September 2009
Christopher Spillane
christopher.spillane@informausa.com
Seaside Therapeutics has raised $30 million to fund the development of its candidates for autism and Fragile X syndrome. The Massachusetts-based firm has secured $66 million in private financing to date.
The company's lead candidate is STX209, a selective GABA-B receptor agonist that has been...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Addex sends allosteric modulator into Phase II for Parkinson's
- US Capitol Capsule: FDA's CDER ends 2011 with 30 new drugs and biologics
- EMA guidance points up challenges to biosimilar interferon beta developers
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
